InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,011.12
(
-0.22%
)
US TECH 100
16,879.60
(
-0.34%
)
Dow Jones
37,775.38
(
0.00%
)
Brent Oil
86.09
(
-0.38%
)
Bitcoin
65,457.81
(
3.07%
)
Post# of 251527
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119431
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 220321

Tuesday, 04/02/2019 9:41:42 AM

Tuesday, April 02, 2019 9:41:42 AM

Post# of 251527
AGN/MOLN.SW—Abicipar pegol (a/k/a DARPin) shows 8.9% ocular inflammation in open-label study with new manufacturing process—lower than the 15% rate in prior phase-3 trials, but still too high to be competitive (IMO):

https://finance.yahoo.com/news/allergan-molecular-partners-announce-topline-110000485.html

AGN, by its own admission, was aiming for an inflammation rate in the low-to-mid single digits.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up